This is the 16th offering/registration filing in 24 months for a $26M market cap pre-revenue biotech, signaling persistent cash burn and reliance on dilutive financing. The $0.76 dilution per new share is substantial relative to the $12 offering price. Watch for continued equity raises and potential further dilution from the 333,333 warrants exercisable at $12.00. The 45-day lock-up expiry and 30-day company standstill may create near-term volume pressure.
Price Chart
Executive Summary
Polyrizon Ltd. filed a 424B5 prospectus supplement for a registered direct offering of 232,500 ordinary shares at $12.00/share and 30,000 pre-funded warrants at $11.99999 each, with a concurrent private placement of 70,833 PIPE pre-funded warrants and 333,333 ordinary share warrants (exercise price $12.00, 5-year term). Total gross proceeds are approximately $3.15 million from the registered portion, with net proceeds to the company of ~$2.9 million. The offering represents ~12.3% dilution from pre-offering shares outstanding, and new investors will suffer immediate dilution of $0.76 per share in net tangible book value. The company has a history of frequent capital raises (16 offering/registration filings in 24 months) and is a pre-revenue development-stage biotech.
Key Facts
- Offering: 232,500 ordinary shares at $12.00/share and 30,000 pre-funded warrants at $11.99999 each (gross proceeds ~$3.15M)
- Concurrent private placement: 70,833 PIPE pre-funded warrants and 333,333 ordinary share warrants (exercise $12.00, 5-year term)
- Net proceeds to company ~$2.9M after 8% placement agent fee (~$252K) and ~$112.5K estimated expenses
- Shares outstanding pre-offering: 2,139,567; post-offering (including pre-funded warrant exercise): 2,402,067
- New investors face immediate dilution of $0.76 per share in net tangible book value
- Company sold ~$7.47M in securities under the same shelf in prior 12 months; 16 offering/registration filings in 24 months
- Lock-up agreements for officers/directors/specified holders for 45 days post-closing; company standstill for 30 days
- Company is a pre-revenue development-stage biotech (nasal hydrogel medical devices); continuing losses and accumulated deficit of $8.4M as of Dec 2025
- Last sale price $12.51 on Sept 2, 2026 (offering priced at slight discount of ~4%)
Financial Impact
Offering raises ~$2.9M net (registered portion) plus concurrent private placement warrants; ~12.3% dilution to existing shareholders; new investors diluted $0.76/share relative to pro forma net tangible book value of $11.24
Risk Factors
- Chronic dilution: 16 capital raises in 24 months for a $26M market cap company suggests structural undercapitalization
- Immediate $0.76/share dilution (6.3% of offering price) for new investors
- Concurrent private placement adds 333,333 warrants exercisable at $12.00 (in-the-money relative to $12.51 last sale), creating future dilution
- Pre-revenue status with accumulated deficit of $8.4M; no guaranteed path to commercialization
- Israeli geopolitical risk (prolonged conflict with Hamas, Hezbollah, Iran) could disrupt operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001213900-26-097441 |
| Document: 0001213900-26-097441-index-headers.html | 0001213900-26-097441 |
| Document: 0001213900-26-097441-index.html | 0001213900-26-097441 |
| Document: 0001213900-26-097441.txt | 0001213900-26-097441 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 6-K | $9.67 $9.15 | ▼ −5.37% | ▼ −5.13% | $8.96 (−7.37%) |
Oct 2, 2026 25d ago | EFFECT | $9.61 $9.26 | ▲ +3.64% | ▲ +4.32% | $8.96 (+6.80%) |
Sep 22, 2026 4w ago | Press Release | $10.66 $11.16 | ▲ +4.69% | ▲ +5.41% | $8.96 (−15.98%) |
Sep 18, 2026 5w ago | F-1 | $10.90 $10.66 | ▲ +2.20% | ▲ +2.19% | $8.96 (+17.83%) |
Sep 4, 2026 7w ago | Press Release | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.96 (+20.31%) |
Sep 4, 2026 7w ago | 6-K | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.96 (+20.31%) |
Sep 4, 2026 7w ago | 424B5 | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.96 (+20.31%) |
Aug 20, 2026 9w ago | 6-K | $10.30 $10.70 | ▲ +3.88% | ▲ +4.18% | $8.96 (−13.04%) |
Jul 13, 2026 15w ago | 6-K | $13.76 $13.07 | ▼ −4.98% | ▼ −5.38% | $8.96 (−34.88%) |
Jul 2, 2026 16w ago | 6-K | $13.80 $15.21 | ▲ +10.20% | ▲ +9.32% | $8.96 (−35.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers